The pathogenesis of AD involves complex immune pathways; certain patients may exhibit dominant non-Th2-mediated inflammation (e.g., Th17 or JAK-STAT activation), potentially limiting dupilumab response (19, 20). The gene discussed is SOAT1; the disease is Alzheimer disease.